92 related articles for article (PubMed ID: 22457820)
1. Prostate cancer risk is not altered by TP53AIP1 germline mutations in a German case-control series.
Luedeke M; Coinac I; Linnert CM; Bogdanova N; Rinckleb AE; Schrader M; Vogel W; Hoegel J; Meyer A; Dörk T; Maier C
PLoS One; 2012; 7(3):e34128. PubMed ID: 22457820
[TBL] [Abstract][Full Text] [Related]
2. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer.
Breyer JP; Avritt TG; McReynolds KM; Dupont WD; Smith JR
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1348-53. PubMed ID: 22714738
[TBL] [Abstract][Full Text] [Related]
3. Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.
Benfodda M; Gazal S; Descamps V; Basset-Seguin N; Deschamps L; Thomas L; Lebbe C; Saiag P; Zanetti R; Sacchetto L; Chiorino G; Scatolini M; Grandchamp B; Bensussan A; Soufir N
Genes Chromosomes Cancer; 2018 Jun; 57(6):294-303. PubMed ID: 29359367
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
Meyer A; Coinac I; Bogdanova N; Dubrowinskaja N; Turmanov N; Haubold S; Schürmann P; Imkamp F; von Klot C; Merseburger AS; Machtens S; Bremer M; Hillemanns P; Kuczyk MA; Karstens JH; Serth J; Dörk T
Urol Oncol; 2013 Jan; 31(1):74-81. PubMed ID: 21396839
[TBL] [Abstract][Full Text] [Related]
5. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.
Karlsson R; Aly M; Clements M; Zheng L; Adolfsson J; Xu J; Grönberg H; Wiklund F
Eur Urol; 2014 Jan; 65(1):169-76. PubMed ID: 22841674
[TBL] [Abstract][Full Text] [Related]
6. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
[TBL] [Abstract][Full Text] [Related]
7. A common nonsense mutation of the BLM gene and prostate cancer risk and survival.
Antczak A; Kluźniak W; Wokołorczyk D; Kashyap A; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Masojć B; Górski B; Gromowski T; Nagorna A; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Borkowski T; Borkowski A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Domagała P; Stawicka M; Milecki P; Akbari MR; Narod SA; Lubiński J; Cybulski C; ; ; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała W; Chosia M; van de Wetering T; Serrano-Fernández P; Puszyński M; Soczawa M; Switała J; Archimowicz S; Kordowski M; Zyczkowski M; Borówka A; Bagińska J; Krajka K; Szwiec M; Haus O; Janiszewska H; Stembalska A; Sąsiadek MM
Gene; 2013 Dec; 532(2):173-6. PubMed ID: 24096176
[TBL] [Abstract][Full Text] [Related]
8. ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.
Siltanen S; Syrjäkoski K; Fagerholm R; Ikonen T; Lipman P; Mallott J; Holli K; Tammela TL; Järvinen HJ; Mecklin JP; Aittomäki K; Blomqvist C; Bailey-Wilson JE; Nevanlinna H; Aaltonen LA; Schleutker J; Vahteristo P
Eur J Hum Genet; 2008 Aug; 16(8):983-91. PubMed ID: 18337727
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Interaction of
Sipeky C; Gao P; Zhang Q; Wang L; Ettala O; Talala KM; Tammela TLJ; Auvinen A; Wiklund F; Wei GH; Schleutker J
Clin Cancer Res; 2018 Dec; 24(24):6265-6276. PubMed ID: 30181389
[TBL] [Abstract][Full Text] [Related]
10. Germline ATBF1 mutations and prostate cancer risk.
Xu J; Sauvageot J; Ewing CM; Sun J; Liu W; Isaacs SD; Wiley KE; Diaz L; Zheng SL; Walsh PC; Isaacs WB
Prostate; 2006 Jul; 66(10):1082-5. PubMed ID: 16637072
[TBL] [Abstract][Full Text] [Related]
11. Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
Wu Y; Yu H; Zheng SL; Feng B; Kapron AL; Na R; Boyle JL; Shah S; Shi Z; Ewing CM; Wiley KE; Luo J; Walsh PC; Carter HB; Helfand BT; Cooney KA; Xu J; Isaacs WB
Prostate; 2018 Dec; 78(16):1222-1228. PubMed ID: 30043417
[TBL] [Abstract][Full Text] [Related]
12. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
13. Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk.
Wang X; Wang F; Taniguchi K; Seelan RS; Wang L; Zarfas KE; McDonnell SK; Qian C; Pan K; Lu Y; Shridhar V; Couch FJ; Tindall DJ; Beebe-Dimmer JL; Cooney KA; Isaacs WB; Jacobsen SJ; Schaid DJ; Thibodeau SN; Liu W
Cancer Res; 2006 Nov; 66(21):10302-7. PubMed ID: 17079449
[TBL] [Abstract][Full Text] [Related]
14. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer.
Jonsson BA; Bergh A; Stattin P; Emmanuelsson M; Grönberg H
Int J Cancer; 2002 Apr; 98(6):838-43. PubMed ID: 11948460
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer.
Agalliu I; Kwon EM; Zadory D; McIntosh L; Thompson J; Stanford JL; Ostrander EA
Clin Cancer Res; 2007 Feb; 13(3):839-43. PubMed ID: 17289875
[TBL] [Abstract][Full Text] [Related]
17. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype.
Rogler A; Rogenhofer M; Borchardt A; Lunz JC; Knoell A; Hofstaedter F; Tannapfel A; Wieland W; Hartmann A; Stoehr R
Pathobiology; 2011; 78(4):193-200. PubMed ID: 21778786
[TBL] [Abstract][Full Text] [Related]
18. Role of functional polymorphisms of P53 and P73 genes with the risk of prostate cancer in a case-control study from Northern India.
Mittal RD; George GP; Mishra J; Mittal T; Kapoor R
Arch Med Res; 2011 Feb; 42(2):122-7. PubMed ID: 21565625
[TBL] [Abstract][Full Text] [Related]
19. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
20. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
